Acorda Therapeutics (ACOR) Insider Trading & Ownership → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Free ACOR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Insider TradesStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Acorda Therapeutics (NASDAQ:ACOR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.60%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$6,084.00Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$3,876.00 Get ACOR Insider Trade Alerts Want to know when executives and insiders are buying or selling Acorda Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ACOR Insider Buying and Selling by Quarter Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.I have uncovered a bombshell that changes everything… and threatens everything. Acorda Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/16/2023Ron CohenCEOBuy507$12.00$6,084.00 3/17/2022Ron CohenCEOSell114$34.00$3,876.00 (Data available from 1/1/2013 forward) ACOR Insider Trading Activity - Frequently Asked Questions Who is on Acorda Therapeutics's Insider Roster? The list of insiders at Acorda Therapeutics includes Ron Cohen. Learn more on insiders at ACOR. What percentage of Acorda Therapeutics stock is owned by insiders? 2.60% of Acorda Therapeutics stock is owned by insiders. Learn more on ACOR's insider holdings. Which Acorda Therapeutics insiders have been buying company stock? The following insider purchased ACOR shares in the last 24 months: Ron Cohen ($6,084.00). How much insider buying is happening at Acorda Therapeutics? Insiders have purchased a total of 507 ACOR shares in the last 24 months for a total of $6,084.00 bought. More Insider Trading Tools from MarketBeat Related Companies: SQZ Insider Trading WINT Insider Trading ELOX Insider Trading SBFM Insider Trading BBLG Insider Trading VRPX Insider Trading BLPH Insider Trading CMRA Insider Trading EVFM Insider Trading NMTR Insider Trading Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 3 Stocks Insiders are Buying That Should be on Your RadarInsider Trading is Good News for These Stocks4 Small-Cap Energy Stocks Insiders are Buying 3 Penny Stocks That Insiders Are BuyingThe 3 Hottest Insiders Buys This Month This page (NASDAQ:ACOR) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.